WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 564900
Description: YSY01A is a proteasome inhibitor which enhances Cisplatin cytotoxicity in Cisplatin-resistant human ovarian cancer cells, thereby inducing cell cycle arrest on G2 phase in MCF-7 cells via ERα and PI3K/Akt pathways.
MedKoo Cat#: 564900
Chemical Formula: C29H38BN5O5
Exact Mass: 547.2966
Molecular Weight: 547.46
Elemental Analysis: C, 63.62; H, 7.00; B, 1.97; N, 12.79; O, 14.61
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
IUPAC/Chemical Name: ((S)-3-Methyl-1-((S)-2-((S)-4-methyl-2-(pyrazine-2-carboxamido)pentanamido)-3-(naphthalen-2-yl)propanamido)butyl)boronic acid
InChi Key: BJJCLDNVNAULGO-KYPHJKQUSA-N
InChi Code: InChI=1S/C29H38BN5O5/c1-18(2)13-23(33-29(38)25-17-31-11-12-32-25)27(36)34-24(28(37)35-26(30(39)40)14-19(3)4)16-20-9-10-21-7-5-6-8-22(21)15-20/h5-12,15,17-19,23-24,26,39-40H,13-14,16H2,1-4H3,(H,33,38)(H,34,36)(H,35,37)/t23-,24-,26+/m0/s1
SMILES Code: CC(C)C[C@H](B(O)O)NC([C@@H](NC([C@@H](NC(C1=NC=CN=C1)=O)CC(C)C)=O)CC2=CC=C3C=CC=CC3=C2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 547.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Huang W, Yuan X, Sun T, Fan S, Wang J, Zhou Q, Guo W, Ran F, Ge Z, Yang H, Li R, Cui J. Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells. Front Pharmacol. 2017 Aug 24;8:476. doi: 10.3389/fphar.2017.00476. eCollection 2017. PubMed PMID: 28883791; PubMed Central PMCID: PMC5574410.
2: Huang W, Zhou Q, Yuan X, Ge ZM, Ran FX, Yang HY, Qiang GL, Li RT, Cui JR. Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells. J Cancer. 2016 Jun 6;7(9):1133-41. doi: 10.7150/jca.14519. eCollection 2016. PubMed PMID: 27326257; PubMed Central PMCID: PMC4911881.
3: Zhang M, Yuan X, Xu B, Guo W, Ran FX, Li RT, Cui JR. Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo. J Cancer. 2015 Jun 11;6(8):701-8. doi: 10.7150/jca.11785. eCollection 2015. PubMed PMID: 26185531; PubMed Central PMCID: PMC4504105.
4: Xue B, Huang W, Yuan X, Xu B, Lou Y, Zhou Q, Ran F, Ge Z, Li R, Cui J. YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways. J Cancer. 2015 Feb 6;6(4):319-26. doi: 10.7150/jca.10733. eCollection 2015. PubMed PMID: 25767601; PubMed Central PMCID: PMC4349871.